Expand PLRZ Menu
PLRZ MENU

PLRZ Latest Press Releases

-- April 7, 2026 --

Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement Globe Newswire 8:00 AM

-- March 26, 2026 --

Polyrizon Provides 2025 and Recent Highlights Globe Newswire 9:23 AM

-- March 25, 2026 --

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 Globe Newswire 5:25 PM

-- March 24, 2026 --

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications Globe Newswire 8:47 AM

-- March 17, 2026 --

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program Globe Newswire 8:25 AM

-- March 10, 2026 --

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study Globe Newswire 7:55 AM

-- February 26, 2026 --

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product Globe Newswire 8:12 AM

-- February 17, 2026 --

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX , Drug-Free Allergy Blocker PRNewswire 11:32 AM

-- February 10, 2026 --

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator Globe Newswire 6:55 AM

-- February 6, 2026 --

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation Globe Newswire 7:55 AM
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI Globe Newswire 7:55 AM

-- February 4, 2026 --

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company Globe Newswire 7:12 AM

-- January 22, 2026 --

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker Globe Newswire 9:25 AM

-- January 13, 2026 --

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet Globe Newswire 8:39 AM

-- January 8, 2026 --

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX Globe Newswire 8:45 AM

-- January 5, 2026 --

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator Globe Newswire 9:07 AM

-- January 2, 2026 --

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated Globe Newswire 8:30 AM

-- December 29, 2025 --

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet Globe Newswire 7:20 AM

-- December 19, 2025 --

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses Globe Newswire 8:20 AM

-- December 11, 2025 --

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program Globe Newswire 8:15 AM

-- December 8, 2025 --

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray Globe Newswire 8:55 AM

-- December 4, 2025 --

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection Globe Newswire 7:32 AM

-- December 3, 2025 --

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product Globe Newswire 9:28 AM

-- December 2, 2025 --

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform Globe Newswire 7:55 AM
Market Data Delayed 15 Minutes